MyPrurigoTeam

Nemluvio (nemolizumab) was recently approved by the FDA in 2024 for prurigo nodularis treatment. Clinical trials showed impressive results - 58% of participants experienced significant itch relief after 16 weeks, and this relief was maintained through 24 weeks of treatment. By the end of the trial period, about 31% of Show Full Answer

Nemluvio (nemolizumab) was recently approved by the FDA in 2024 for prurigo nodularis treatment. Clinical trials showed impressive results - 58% of participants experienced significant itch relief after 16 weeks, and this relief was maintained through 24 weeks of treatment. By the end of the trial period, about 31% of people achieved total or near-total skin clearance. While the medication shows promise, it's important to note that it can have some side effects, though they're typically mild to moderate. These may include headaches and eczema. The medication is given as an injection under the skin once every four weeks, which is less frequent than Dupixent's every-two-weeks schedule. As with any medication, results can vary from person to person, so it's best to discuss with your healthcare provider about whether Nemluvio might be the right choice for your specific situation.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

58% Saw Itch Relief and 31% Had Skin Clearance From Nemolizumab